U.S. Markets close in 4 hrs 31 mins

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABMD, CVS and CADE

NEW YORK, NY / ACCESSWIRE / October 6, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Abiomed, Inc. (ABMD)
Class Period: January 31, 2019 to July 31, 2019
Lead Plaintiff Deadline: October 7, 2019

The lawsuit alleges that throughout the class period, Abiomed, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed's revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company's prior projections and market expectations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ABMD: http://www.kleinstocklaw.com/pslra-1/abiomed-inc-loss-submission-form?id=3824&from=1

CVS Health Corporation (CVS)
Class Period: on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS's acquisition of Aetna on November 28, 2018.
Lead Plaintiff Deadline: October 15, 2019

According to the filed complaint, CVS made false and/or misleading statements in connection with its acquisition of Aetna and/or failed to disclose that: (a) by the end of 2017, CVS's financial condition and expected earnings had deteriorated as a result of rising costs and poor results being experienced in the long-term care ("LTC") unit associated with the 2015 acquisition of Omnicare; (b) in 2017, deteriorating conditions and prospects in CVS 's LTC unit prompted CVS to undertake hasty acquisitions of LTC pharmacies to compensate for the declining LTC business and/or mask the expected LTC goodwill impairment ahead of the planned Acquisition; (c) although negative LTC performance factors prompted CVS and the CVS Individual Defendants to make hasty LTC pharmacy acquisitions in 2017, those same negative factors were being overlooked and ignored for purposes of undertaking, disclosing, and reporting the results of LTC goodwill impairment tests throughout 2017, in violation of GAAP; (d) the LTC goodwill being carried on CVS's books as a result of the Omnicare acquisition was being carried at inflated values that would require billions of dollars in impairment charges that would be charged against earnings; and (e) as a result of the foregoing, CVS's true business metrics and financial prospects were not as the Offering Documents represented.

Learn about your recoverable losses in CVS: http://www.kleinstocklaw.com/pslra-1/cvs-health-corporation-loss-submission-form-2?id=3824&from=1

Cadence Bancorporation (CADE)
Class Period: July 23, 2018 to July 22, 2019
Lead Plaintiff Deadline: November 15, 2019

Cadence Bancorporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate internal controls to assess credit risk; (2) as a result, certain of the Company's loans posed an increased risk of loss; (3) as a result, the Company was reasonably likely to incur significant losses for certain loans; (4) the Company's financial results would suffer a material adverse impact; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in CADE: http://www.kleinstocklaw.com/pslra-1/cadence-bankcorporation-loss-submission-form?id=3824&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/562124/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ABMD-CVS-and-CADE